Related Experiment Video

Updated: Aug 1, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Danielle Brazel1, Jennifer Kim1, Sai-Hong Ignatius Ou1,2

  • 1University of California Irvine School of Medicine, Department of Internal Medicine, Division of Hematology-Oncology, Orange, CA, USA.

Lung Cancer (Auckland, N.Z.)
|April 27, 2023
PubMed

Insights

Sotorasib, a targeted therapy for KRAS G12C-mutated lung cancer, shows promise. Despite debate, its approval and improved progression-free survival mark a breakthrough in treating this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • KRAS G12C mutations occur in 14% of lung adenocarcinoma, particularly in smokers.
  • Targeting KRAS G12C was historically challenging due to protein structure and rapid GTP hydrolysis.
  • Sotorasib is the first-in-class covalent inhibitor targeting the KRAS G12C-GDP 'off' state.

Purpose of the Study:

  • To evaluate the efficacy and clinical impact of sotorasib in KRAS G12C-mutated non-small cell lung cancer (NSCLC).
  • To discuss the significance of sotorasib's approval and clinical trial results in the context of targeted cancer therapy.

Main Methods:

  • Analysis of Phase II CodeBreaK 100 trial data for sotorasib in KRAS G12C+ NSCLC.
  • Comparison of sotorasib's progression-free survival (PFS) against docetaxel at the European Society of Medical Oncology (ESMO) 2022 annual meeting.

Main Results:

  • Sotorasib demonstrated an objective response rate (ORR) of 36% and median response duration of 10 months in 124 patients.
  • Sotorasib showed a statistically significant improvement in PFS over docetaxel (HR=0.66, P=0.002), extending PFS by 1.1 months.
  • The ORR was 28% in the comparative analysis, prompting debate on clinical significance.

Conclusions:

  • Sotorasib represents a significant advancement in targeted therapy for KRAS G12C-mutated NSCLC.
  • Despite modest PFS gains, sotorasib's approval and efficacy data support its classification as a breakthrough treatment.
  • Further research and debate are warranted to fully understand sotorasib's long-term impact and optimal use.
Keywords:
CodeBreaKKRAS G12C mutationsadagrasibdocetaxelnon-small-cell lung cancersotorasib

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K